Wegovy Weight-Loss Pills Approved for Use in the UK

The landscape of obesity treatment in the United Kingdom changed this week as the Medicines and Healthcare products Regulatory Agency (MHRA) officially approved a pill version of the popular weight-loss drug, Wegovy. This decision makes the UK the third country in the world to authorize the tablets, following the United States and the United Arab Emirates. For many patients, this development offers a new way to manage their health without the need for weekly injections.

According to BBC Health, the pill contains semaglutide, the same active ingredient found in the injectable version of the drug. Semaglutide works by mimicking a natural hormone in the body called GLP-1. This hormone helps to suppress appetite and slows down digestion, which keeps people feeling full for longer periods. Clinical trials cited by The Guardian showed that patients taking the highest dose of the medication lost between 14% and 17% of their body weight over 64 weeks.

Manufacturer Novo Nordisk noted that the once-a-day tablet could be more convenient for many users. Unlike the injectable version, which must be kept in a refrigerator, the pills are easier to store and travel with. Olivier Picard, the Chair of the National Pharmacy Association, described the approval as a significant step forward. He suggested that the pill might help patients who are unable or unwilling to use needles, and it could potentially lower the cost of treatment over the long term.

Despite this approval, the medication will not be available through the National Health Service (NHS) immediately. The National Institute for Health and Care Excellence (Nice) must first assess the drug to decide if it should be recommended for wider public use. For now, patients who wish to access the treatment will need to obtain a private prescription. While the exact cost for the UK market has not been set, private prescriptions for the injectable version currently range from £90 to £300 per month, depending on the dosage.

Medical experts are urging caution, reminding the public that these drugs are not a "magic solution" for weight loss. Prof Victoria Tzortziou Brown, president of the Royal College of GPs, emphasized that the medication is intended for adults who are obese or overweight with at least one weight-related health condition. She stressed that the pills should always be used as part of a broader approach to health, which must include proper nutrition, regular physical activity, and behavioral support. Like any medication, the pills can cause side effects, including nausea, vomiting, diarrhea, and constipation.

This approval comes at a time when the medical community is increasingly interested in the versatility of GLP-1 receptor agonists. As reported by Deutsche Welle, these drugs were originally developed to treat type 2 diabetes but are now being studied for a wide range of other benefits. Researchers are looking into whether these medications can protect the heart, liver, and kidneys, or even reduce inflammation and the risk of certain cancers. This concept, known as "drug repurposing," involves finding new uses for existing medications to address different health crises.

However, health officials warn against using these drugs for cosmetic purposes or as a quick fix to get ready for the beach. The MHRA has provided clear instructions for starting the medication, with doses that increase over several months to ensure safety. Patients are advised to take the tablet on an empty stomach with a sip of water and to avoid food or drink for at least 30 minutes afterward. Anyone experiencing side effects is encouraged to report them through the official yellow card scheme.

As pharmacies prepare to add the treatment to their services in the coming weeks, the focus remains on safe and appropriate use. With obesity rates in the UK at very high levels, many doctors agree that having more effective treatment options is a positive step. However, as Prof Naveed Sattar from the University of Glasgow noted, the goal remains to help people sustainably manage their health in an environment that makes maintaining a healthy weight increasingly difficult.